Insili Intelligence (03696) and Haizheng Pharmaceutical (600267.SH) AI accelerate R&D and delivery key milestones in 8 months

The Zhitong Finance App learned that insilicon (03696), a clinical-stage drug development technology company driven by generative artificial intelligence, announced that it has achieved a milestone in a project in the field of innovative drug research and development in cooperation with Haizheng Pharmaceutical (600267.SH). Relying on Pharma.AI, the company's self-developed artificial intelligence drug development platform, the two sides completed the nomination of pre-clinical candidate compounds (PCC) for the cooperation project only about 8 months after reaching a strategic cooperation.

According to public information, this collaboration began in April 2025. Xiao Weihong, Chairman and President of Haizheng Pharmaceutical, and Ren Feng, Co-CEO and Chief Scientific Officer of Insili Intelligence, signed a strategic cooperation agreement on innovative drug research and development at Haizheng Pharmaceutical's R&D headquarters. According to the agreement, the two sides will carry out in-depth collaboration in the field of specific indications around selected targets, and accelerate the discovery and development of innovative drugs by combining artificial intelligence technology with the advantages of traditional drug research and development.

In terms of the specific division of labor, Insili Intelligence is mainly responsible for the early development process from target identification to PCC nomination, including AI-based target analysis, lead compound discovery and structural optimization, and key pre-clinical research; Haizheng Pharmaceutical is responsible for supporting research work related to new drug clinical trial applications (INDs) and promoting subsequent clinical trial reporting and implementation.

According to reports, within 8 months of cooperation, Insili Intelligence relied on its Pharma.AI platform to efficiently advance early project research and development, and completed the pre-clinical research required to support PCC nominations. The pre-clinical data generated by the project has passed Haizheng Pharmaceutical's internal evaluation and is in line with the PCC nomination criteria jointly set by both parties. According to the arrangements set by the two parties, Haizheng Pharmaceutical will take the lead in continuing to advance the subsequent project.

Insilicon Intelligence said that the cooperation with Haizheng Pharmaceutical reached its first milestone in a relatively short period of time and is another vivid example of early development of innovative drugs driven by artificial intelligence. This collaboration focuses on relatively novel targets and targets disease fields where there are huge unmet clinical needs. It is a promising direction for artificial intelligence innovation. With the support of the Pharma.AI platform, Insilicon Intelligence is committed to systematically explore a broad biological and chemical space in a shorter period of time to bring more innovative treatment solutions to patients.

Haizheng Pharmaceutical said it was impressed by the efficiency and quality of this cooperative project to nominate pre-clinical candidate compounds within 8 months. The progress of the project fully demonstrates the acceleration and efficacy of artificial intelligence in the new drug development process. The cooperation with Insili Intelligence not only enhanced Haizheng Pharmaceutical's ability to innovate in early drug development projects, but also marked a key step in the company's digital and intelligent transformation. Haizheng Pharmaceutical believes that the deep integration of traditional pharmaceutical experience with cutting-edge AI technology will help the company lay out innovation pipelines with higher quality and higher efficiency, and continue to provide patients with more valuable treatment options.

The collaboration achieved PCC nomination in a short period of time. It is a verification of Insilisic's intelligent delivery capabilities and collaborative efficiency between the two parties. It not only reflects the potential advantages of generative artificial intelligence in improving the efficiency of innovative drug development, shortening the R&D cycle and optimizing costs, but also provides a representative practical case for local companies to explore new paths of innovative drug development through the “AI platform + pharmaceutical industrialization capability” collaborative model.